M&A / Deals Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership Pharmaceutical TechnologyEli Lilly's deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.Gene Therapy PlatformRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) Pharmaceutical Technology Eli Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellares and TScan to assess automated manufacturing of TSC-101 therapyNext: Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
